CTL019

Novartis kickbacks case explodes with feds demand for backup on 80000 doctor events

Financials

Cancer activist concerned about Novartis' CAR-T pricing

Cancer patient and advocate David Mitchell visited Novartis to discuss what a fair price might be for its CAR-T treatment, but he left disappointed.

Arlene Weintraub Aug 30, 2017 9:00am

Joe Jimenez

Cosentyx sales double, aiding Novartis Q2 earnings beat

Jul 18, 2017 11:13am

Human T cell

Oxford BioMedica and Novartis build on cell therapy supply deal

Jul 6, 2017 8:53am

novartis

How will Novartis price CAR-T? Here are some clues

Jun 8, 2017 10:17am